


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof;



wherein ;


R_1 is selected from groups (a), (b), and (c) wherein;

(a) is ~~C7-C20 alkyl, C7-C20 haloalkyl, C7-C20 alkenyl, C7-C20 alkynyl, carbocyclic radical, or heterocyclic radical, or~~

(b) is ~~a member of (a) substituted with one or more independently selected non-interfering substituents; or~~

(c) is the group $-(L_1)-R_{11}$; where, $-(L_1)-$ is an alkylene chain of 1 to 8 carbon atoms and where R_{11} is ~~a group selected from (a)~~

~~or (b)~~ is $-(CH_2)_m-R_{12}$; wherein m is an integer from 0 to 2; and R_{12} is the group




represented by the formula:


where n is an integer from 0 to 2 and p is an integer from 0 to 2; and R_{13} is selected from C_1 to C_8 alkyl;

R_2 is hydrogen, or C_1 - C_4 alkyl;

R₃ is -(L₃)- Z, where -(L₃)- is a ~~divalent linker group selected from a bond or:~~




and Z is a group represented by the formulae,



wherein, X is oxygen ~~or sulfur~~; and R_a is selected from hydrogen, C₁-C₈ alkyl, aryl, C₁-C₈ alkaryl, C₁-C₈ alkoxy, aralkyl and -CN;


R₄ is the group, -(L_h)-(hydroxyfunctional amide); wherein -(L_h)-, is ~~an~~ hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8 represented by the formula



Q₂ is O;

R⁴⁰ is independently selected from hydrogen and C₁-C₈ alkyl;

(Hydroxyfunctional amide) is the group



wherein R^{4a} is OH;

R^{4b} is selected from the group consisting of H and C_1 - C_8 alkyl;


R_5 is selected from hydrogen, a non-interfering substituent, or the group, (L_a) (acidic group); wherein (L_a) is an acid linker having an acid linker length of 1 to 8; and

R_6 and R_7 are independently selected from the group consisting of hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl.


2. (Cancelled)

3. (Cancelled)

4. (Currently Amended) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, $-(L_h)-$, for R_4 is a divalent group selected from,



or




where R_{40} , R_{41} , R_{42} , and R_{43} are each independently selected from hydrogen, C_1 - C_8 alkyl.

5. (Cancelled)

6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)

18. (Currently Amended) The compound of claim 1 wherein R₄ is the group, ~~-(L_e)-(hydroxyfunctional-(L_h)-(hydroxyfunctional~~ amide group) and wherein the (hydroxyfunctional amide group) is:



and R^{4a} is independently selected from the group consisting of OH, ~~(C₁-C₆)alkoxy, (C₇-C₁₄)alkaryloxy, (C₂-C₈)alkenyloxy, (C₇-C₁₄)aralkyloxy, (C₇-C₁₄)aralkenyloxy and aryloxy;~~ and

wherein R^{4b} is (C₁-C₆)alkyl.

~~wherein R^{4b} is independently selected from the group consisting of H, (C₁-C₆)alkyl, arylalkyl, heteroaryl and aryl.~~

19. (Cancelled)

20. (Previously Presented) A compound selected from the group of:
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyloxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(methyloxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(methyl)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(ethyloxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(2-propenyloxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(2-propyl)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(tert-butyloxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-[2-(methyl)propyloxy]acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenylmethyloxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenylmethyloxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenyloxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenyloxy)acetamide;
- 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(cyclohexyl)-*N*-(hydroxy)acetamide; and
- 2-[[3-(2-Amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide.

21. (Cancelled)

22. (Original) A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. (Cancelled)

24. (Cancelled)

25. (Previously Presented) A pharmaceutical formulation containing an effective amount of the compound of claim 1 useful for the treatment and/or amelioration of Inflammatory Diseases.

26. (Cancelled)

27. (Cancelled)